BRD7

BRD7 (bromodomain-containing protein 7) is a bromodomain-containing chromatin regulator that functions as a subunit of the PBAF SWI/SNF chromatin-remodeling complex, where it contributes to chromatin remodeling and transcriptional regulation through recognition of acetylated lysine residues on histones^[1][2]. Mechanistically, BRD7 participates in gene regulatory programs controlling cell-cycle progression, senescence, apoptosis, and proliferation, and it cooperates with transcriptional regulators such as p53 to support transcriptional responses linked to growth control^[2]. In disease contexts, altered BRD7 expression has been reported in multiple malignancies, including nasopharyngeal carcinoma, ovarian cancer, non-small-cell lung cancer, and prostate cancer models, highlighting its relevance to cancer biology and epigenetic regulation^[2][3]. Compared with the closely related bromodomain protein BRD9, BRD7 is incorporated into the PBAF complex, whereas BRD9 is a defining component of the non-canonical BAF/GBAF complex, indicating distinct chromatin-remodeling functions despite structural homology between their bromodomains^[3][4]. This functional distinction has motivated efforts to develop selective chemical tools capable of separating BRD7-dependent biology from BRD9-mediated effects^[3]. For experimental applications, recent structure-guided studies identified a BRD7-specific binding pocket and enabled the development of selective BRD7 bromodomain inhibitors, providing research tools for investigating BRD7 function in cancer-related pathways and chromatin-regulatory mechanisms^[3]. These advances support the use of BRD7-selective probes for mechanistic studies of transcriptional regulation and disease-associated chromatin remodeling^[3].